What it's for (Indications)
- Latanoprost is a prostaglandin F2α analogue primarily indicated for the reduction of elevated intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma or ocular hypertension.
- These conditions are characterized by increased pressure within the eye, which can lead to progressive damage to the optic nerve and, if left untreated, irreversible vision loss.
- By effectively lowering IOP, latanoprost helps to mitigate the risk of optic nerve damage and preserve visual function.
- It is often considered a first-line treatment option due to its potent IOP-lowering efficacy and favorable once-daily dosing regimen.
- The therapeutic goal is to achieve and maintain an intraocular pressure level that is deemed safe and non-damaging for the individual patient's optic nerve.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for latanoprost ophthalmic solution (e.g., Xalatan 0.005%) is one drop in the affected eye(s) once daily, preferably in the evening. Administering the medication in the evening maximizes its IOP-lowering effect during the overnight period. It is crucial to adhere strictly to the once-daily dosing schedule; exceeding this frequency (e.g., twice daily) has been shown to reduce the IOP-lowering efficacy rather than enhance it. If a dose is missed, treatment should continue with the next scheduled dose. If other topical ophthalmic medications are being used concurrently, there should be an interval of at least five minutes between the instillation of each medication to ensure proper absorption and to prevent 'wash-out' of the preceding drop. Patients wearing contact lenses should remove them prior to instillation and wait at least 15 minutes before reinserting them. |
Safety & Warnings
Common Side Effects
- Patients using latanoprost may experience a range of side effects, primarily affecting the eyes.
- The most common ocular adverse reactions include conjunctival hyperemia (redness of the eye), ocular irritation (stinging, burning, itching), foreign body sensation, punctate keratitis, and blurred vision.
- Of significant note are the gradual and potentially permanent changes in iris pigmentation, which manifest as an increased brown color, particularly in eyes with mixed color irises.
- Eyelash changes, such as increased length, thickness, pigmentation, and number, are also commonly observed and are usually reversible upon discontinuation.
- Less common but reported side effects include headache, rash, muscle/joint pain, and upper respiratory tract infections.
- Any severe or persistent ocular pain, discomfort, vision changes, or signs of inflammation should be immediately reported to a healthcare professional.
Serious Warnings
- Black Box Warning: Latanoprost (e.g., Xalatan) does not carry a formal FDA Black Box Warning. However, healthcare professionals and patients should be acutely aware of several serious warnings and significant risks associated with its use. A key concern is the potential for gradual and progressive changes in iris pigmentation, leading to an increase in brown pigment, which can result in permanent heterochromia. Patients with mixed-color irides are at higher risk for this effect. Furthermore, changes in eyelashes (increased length, thickness, pigmentation, and number) and vellus hair may occur, although these are typically reversible upon discontinuation of treatment. Macular edema, including cystoid macular edema, has been reported, particularly in aphakic or pseudophakic patients with a torn posterior lens capsule or other known risk factors. There is also a documented risk of reactivation of herpes simplex keratitis. Thorough patient counseling regarding these potential adverse effects and ongoing monitoring are essential during treatment with latanoprost.
- Several important warnings are associated with latanoprost use.
- A significant concern is the potential for gradual, irreversible changes in iris pigmentation, leading to increased brown color.
- Patients with mixed-color irises are particularly susceptible, and this change may result in permanent heterochromia.
- Latanoprost can also induce changes in eyelashes and vellus hair, including increased length, thickness, pigmentation, and number; these changes are typically reversible upon discontinuation.
- Macular edema, including cystoid macular edema, has been reported, particularly in aphakic or pseudophakic patients with a torn posterior lens capsule, or those with known risk factors for macular edema.
- There is a potential for reactivation of herpes simplex keratitis, thus caution is advised in patients with a history of this condition.
- Contact lenses must be removed prior to instillation and can be reinserted 15 minutes later.
- Latanoprost should be used with caution in patients with active intraocular inflammation (e.
- g.
- , uveitis, iritis).
How it Works (Mechanism of Action)
Latanoprost is a synthetic prostaglandin F2α analogue that functions as a prodrug. Upon topical ocular administration, it is rapidly absorbed through the cornea where it undergoes hydrolysis by esterases to its biologically active free acid form, latanoprost acid. Latanoprost acid then acts as a selective prostanoid FP receptor agonist. Its primary pharmacological effect involves increasing the outflow of aqueous humor from the eye. This enhanced drainage occurs predominantly via the uveoscleral pathway, which is considered the non-conventional outflow route. By increasing the rate at which aqueous humor exits the eye, latanoprost effectively reduces elevated intraocular pressure. This reduction in IOP is crucial for alleviating the pressure on the optic nerve, thereby preventing damage and preserving visual field in patients with open-angle glaucoma and ocular hypertension.